Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance: still low after 7 years.

Objective: The purpose of this study (the third in a series of similar studies) is to evaluate the prevalence of Staphylococcus aureus (SA), methicillin-resistant SA (MRSA) and mupirocin-resistant SA (MuRSA) carriers in a peritoneal dialysis centre where patients have been instructed to use prophylactic mupirocin ointment at the catheter exit site over the last 7 years.

Methods: Swabs were taken from catheter exit site, nares, axillae and groin in 147 chronic peritoneal dialysis out-patients between November 2003 and January 2004. Axillae/groin and nasal samples were pooled and cultured in the same medium, whereas exit site swabs were cultured separately.

Prevalence and determinants of erectile dysfunction in patients on peritoneal dialysis.

Background: Sexual dysfunction including erectile dysfunction (ED) is common in patients with end stage renal disease on peritoneal dialysis (PD). Prevalence and determinants of ED in these patients has not been well characterized.

Patients And Methods: Prevalence of ED in 44 patients on chronic PD was assessed using the International Index of Erectile Function (IIEF-5) commonly called Sexual Health Inventory for Men (SHIM) score.